IFRX - InflaRx N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.08
+0.56 (+1.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close46.52
Open47.49
Bid42.50 x 800
Ask48.45 x 1100
Day's Range45.75 - 47.50
52 Week Range20.31 - 51.33
Volume287,611
Avg. Volume112,626
Market Cap1.208B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.39
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.25
Trade prices are not sourced from all markets
  • InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year
    Simply Wall St.8 days ago

    InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year

    These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick the right individual stocks, you could make moreRead More...

  • GlobeNewswire20 days ago

    InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

    InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the approval of a Clinical Trial Application by Health Canada for a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1, in Pyoderma Gangraenosum. This is the third autoimmune disease for which InflaRx is developing IFX-1.

  • GlobeNewswire23 days ago

    Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Richard Brudnick to Join InflaRx Board of Directors

    InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Mr. Richard Brudnick has been appointed as interim Non-Executive Director to the Board of Directors of InflaRx N.V. Mr. Brudnick has substantial experience in the biotechnology and healthcare industry and is currently serving as Chief Business Officer and Head of Strategy for Codiak BioSciences. The confirmed appointment of Mr. Brudnick as a Non-Executive Director of the Board is subject to the approval at the Annual General Meeting of Shareholders in May 2019.

  • GlobeNewswirelast month

    InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that new clinical data with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate to severe Hidradenitis Suppurativa (HS) are to be presented this week at the 8th Conference of the European Hidradenitis Suppurativa Foundation in Wrocław, Poland. HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options.

  • GlobeNewswire2 months ago

    InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced the opening of the company’s second U.S.-based location and the addition of new management members. The new corporate office follows the opening of the company’s R&D facility in Ann Arbor, MI in June 2018.

  • Is InflaRx N.V. (IFRX) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is InflaRx N.V. (IFRX) A Good Stock To Buy?

    Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • GlobeNewswire4 months ago

    InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results

    Completion of patient recruitment in phase IIb trial in Hidradenitis SuppurativaFirst patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis Board of Directors.

  • GlobeNewswire4 months ago

    InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that patient enrollment has been completed in the phase IIb study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS). HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options.

  • GlobeNewswire5 months ago

    InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV). AAV is a rare and life-threatening autoimmune disease in which activation of the complement system, and specifically the generation of larger amounts of C5a, is believed to play a key role in the neutrophil-driven vessel inflammation that defines the disease. AAV affects approximately 40,000 and 75,000 patients in the United States and Europe, respectively.